Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by macman1519on Mar 26, 2018 1:42pm

119 Views

Post# 27782748

RE:RE:RE:RE:Economics improving

And yaz, minimize this, too!!!

LaserStock29 wrote: Repost

LaserStock29 wrote: Yes the FDA provided guidance for our trial specifically Part 2 of Kereport Nov 21,2016

of note P.Obama signed Cures act Dec 13,2016

Kereport Part 2

1:30-3:00 FDA recognizes the need for an alternative therapy.. very involved, provided info on type of patient treated and what outcomes they want to see for new drug approval.

LaserStock29 wrote: Some links and combination of a few key links

Sanofi to Stop production of BCG

BCG Live attenuated, indicated for the treatment of non-muscle invasive bladder cancer. Production will cease mid-2017; however we expect to continue to supply doses to Canada, France, and the UK - where the product is currently available -until the end of 2018.

Merck and demand problems

We already know Merck has a poor track record of keeping up with demand. Shortages will begin appearing in weeks after the Sanofi drug stops shipping in 2017. Patients will suffer irreparable harm once more.

Looks to me that since 2012 this has been an issue... i.e. phasing out or a desire to phase out BCG all together.

I hope Phase 2 gets a bump to first line standing

---------------------------------------

Nov 30 Cures act Dr.Gottlieb

Just incase people wonder where i get the 'outsized, intermediate endpoint, post market confirmatory study thought pattern.

Cures act article 2

Rather than wait for a significant number of clinical trials for a potentially groundbreaking targeted therapy that has outsized benefits, the FDA may consider granting approval earlier and requiring post-market studies to confirm the earlier findings, according to his testimony.

Moving forward, Dr Gottlieb also wants to better define intermediate endpoints under accelerated approval to ensure that drug developers are able to take advantage of the provision and can consider it in a wider scope.

The FDA is considering a similar proposal for oncology drugs seeking a supplemental approval to use a more targeted data set when appropriate. This approach may be suitable when there is an outsized treatment effect and the second indication is for the same disease but in a different setting, according to the release.

i.e Cancer of the bladder, Cancer of the Lung

LaserStock29 wrote: 7 major markets triple by 2025 360m to 1.1b

Cai Xuan, Ph.D., Healthcare Analyst for GlobalData, explains: “Though these PD-1 modulators are expected to have a significant impact on the treatment of bladder cancer, the reality is that the majority of these patients – upwards of around 70% – will not respond to these drugs. In this way, pharmaceutical companies are looking at various ways to expand the treatable patient population. Strategies being employed include expanding into the non-muscle-invasive bladder cancer setting and using combination regimens to boost response rates.

“While big pharmaceutical companies are focused on ‘me-too’ PD-1 modulators, smaller companies are developing drugs with novel mechanisms of action, including Cold Genesys, Eleven Biotherapeutics, and FKD Therapies Oy. GlobalData believes that the bladder cancer market is an attractive prospect for these companies due to the combination of a high level of unmet need and relatively low regulatory hurdles, which provides a suitable risk–reward balance for developers with limited financial resources.”

ROGER 10-4.................. HELLO!!!!!!!!

I got a combination regime

Merck in Q4 2018 is only BCG producer and has our TLD-1433 contract

We're a 'second line' treatment after the SOC of BCG

Sounds like a perfect opportunity to have Merck negotiate a way to empty it's stores and max profit on BCG while being able to capitalize on TLT's TLD-1433

If only the Cures act came through and conditional nod us....

man.. every shred of DD I do.. it's just unbelieveable the story unfolding..

A good ship needs wind at her back for the journey... all the evidence I find is completly in our favor.

The only think u never hear about is our CEO pursuing anything...

That's why i hope P9 gets treated real soon.

................but ya. lets do a PP right... destroy shareholder value when the demand for a new treatment has never been higher and we're 6/6 perfect for multi-treatment